Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Bottom Line: Treatment allocation was not masked.Comparison of 74 Gy in 37 fractions, 60 Gy in 20 fractions, and 57 Gy in 19 fractions groups at 2 years showed no overall bowel bother in 269 (66%), 266 (65%), and 282 (65%) men; very small bother in 92 (22%), 91 (22%), and 93 (21%) men; small bother in 26 (6%), 28 (7%), and 38 (9%) men; moderate bother in 19 (5%), 23 (6%), and 21 (5%) men, and severe bother in four (<1%), three (<1%) and three (<1%) men respectively (74 Gy vs 60 Gy, ptrend=0.64, 74 Gy vs 57 Gy, ptrend=0·59).We saw no differences between treatment groups in change of bowel bother score from baseline or pre-radiotherapy to 24 months.
Affiliation: The Institute of Cancer Research, London, UK.Show MeSH
Related in: MedlinePlus
Mentions: Figure 3 shows change from baseline for UCLA-PCI domain scores and EPIC domain summary scores; additional EPIC domain scores are shown in the appendix (p 10). There were no significant differences between treatment groups. For all urinary and bowel items and domain scores, to maximise numbers, the pre-radiotherapy score was used as a surrogate baseline score unless missing, in which case the baseline score was used; exact numbers are: 749 pre-radiotherapy plus 65 baseline for change in UCLA-PCI bowel function to 24 months; 146 plus 14 for change in EPIC bowel summary to 24 months; 751 plus 64 for change in UCLA-PCI urinary function to 24 months; and 139 plus 16 for change in EPIC urinary summary to 24 months (numbers per treatment group shown in appendix p 14).